Citius Oncology (NASDAQ:CTOR) Posts Earnings Results, Hits Estimates

Citius Oncology (NASDAQ:CTOR) released its quarterly earnings results on Friday. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06), FiscalAI reports. The firm had revenue of $3.94 million for the quarter, compared to the consensus estimate of $4.37 million.

Citius Oncology Stock Up 1.3%

NASDAQ CTOR traded up $0.02 during mid-day trading on Friday, reaching $1.20. The stock had a trading volume of 177,110 shares, compared to its average volume of 223,318. Citius Oncology has a 1 year low of $0.55 and a 1 year high of $6.19. The stock has a market cap of $105.49 million, a PE ratio of -3.51 and a beta of 3.09. The company has a fifty day moving average price of $1.12 and a 200 day moving average price of $1.51. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.56 and a quick ratio of 0.11.

Institutional Trading of Citius Oncology

A number of institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC lifted its stake in shares of Citius Oncology by 31.6% in the 4th quarter. Geode Capital Management LLC now owns 220,047 shares of the company’s stock worth $220,000 after purchasing an additional 52,875 shares during the period. Armistice Capital LLC purchased a new stake in Citius Oncology during the third quarter valued at approximately $15,582,000. Citadel Advisors LLC purchased a new stake in Citius Oncology during the third quarter valued at approximately $36,000. Bank of America Corp DE raised its position in Citius Oncology by 5,256.9% in the second quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after acquiring an additional 8,411 shares during the period. Finally, Jane Street Group LLC purchased a new position in shares of Citius Oncology during the 2nd quarter worth $465,000. Institutional investors own 70.52% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Oncology in a research report on Monday, December 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Citius Oncology currently has an average rating of “Hold” and an average price target of $6.00.

Citius Oncology Company Profile

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.